女性的雄激素:皮肤病的激素调节疗法。

PubMed ID
G H
发表日期 2019年Jun月

原始出处 美国皮肤病学会杂志
Journal of the American Academy of Dermatology
作者 Azarchi  Sarah  Bienenfeld  Amanda  Lo Sicco  Kristen  Marchbein  Shari  Shapiro  Jerry  Nagler  Arielle R 

文献标题 女性的雄激素:皮肤病的激素调节疗法。
Androgens in women: Hormone-modulating therapies for skin disease.
Androgens in women: Hormone-modulating therapies for skin disease.

文献摘要

雄激素介导的女性皮肤疾病(amcd),包括痤疮、多毛症和女性脱发,可以用激素调节疗法来治疗。在继续医学教育系列的第二篇文章中,我们讨论了皮肤科医生可用于治疗AMCDs的激素调节疗法,包括联合口服避孕药、螺内酯、非那雄胺、度他雄胺和氟他胺。对每一种amcd可用的激素调节治疗方法进行了综述,包括雄激素调节机制、安全性、禁忌症、监测参数和疗效证据。讨论的药物包括美国食品和药物管理局批准用于某些amcd的药物和一些非标签使用的药物。尽管激素调节疗法在AMCDs中的应用非常普遍,但这篇综述强调了对痤疮、多毛症和女性脱发进行更严格研究的必要性。


Androgen-mediated cutaneous disorders (AMCDs) in women, including acne, hirsutism, and female pattern hair loss, can be treated with hormone-modulating therapies. In the second article in this Continuing Medical Education series, we discuss the hormone-modulating therapies available to dermatologists for the treatment of AMCDs, including combined oral contraceptives, spironolactone, finasteride, dutasteride, and flutamide. Available hormone-modulating treatments used for each AMCDs are reviewed, along with mechanisms of androgen modulation, safety profile, contraindications, monitoring parameters, and evidence of efficacy. Medications discussed include those that are approved by the US Food and Drug Administration for certain AMCDs and some that are used off-label. Despite the ubiquity of hormone-modulating therapies used for AMCDs, this review highlights the need for more rigorous studies to evaluate these therapies for acne, hirsutism, and female pattern hair loss.

Androgen-mediated cutaneous disorders (AMCDs) in women, including acne, hirsutism, and female pattern hair loss, can be treated with hormone-modulating therapies. In the second article in this Continuing Medical Education series, we discuss the hormone-modulating therapies available to dermatologists for the treatment of AMCDs, including combined oral contraceptives, spironolactone, finasteride, dutasteride, and flutamide. Available hormone-modulating treatments used for each AMCDs are reviewed, along with mechanisms of androgen modulation, safety profile, contraindications, monitoring parameters, and evidence of efficacy. Medications discussed include those that are approved by the US Food and Drug Administration for certain AMCDs and some that are used off-label. Despite the ubiquity of hormone-modulating therapies used for AMCDs, this review highlights the need for more rigorous studies to evaluate these therapies for acne, hirsutism, and female pattern hair loss.


获取全文 10.1016/j.jaad.2018.08.061